Scarica l'app Stockscreener
0.569
7.48%
-0.046
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.615
Aprire:
$0.5966
Volume 24 ore:
192.88K
Relative Volume:
0.39
Capitalizzazione di mercato:
$18.89M
Reddito:
-
Utile/perdita netta:
$-98.79M
Rapporto P/E:
-0.174
EPS:
-3.27
Flusso di cassa netto:
$-51.66M
1 W Prestazione:
-9.02%
1M Prestazione:
-9.68%
6M Prestazione:
+49.74%
1 anno Prestazione:
-83.22%
Intervallo 1D:
$0.5671
$0.61
Intervallo di 1 settimana:
$0.5671
$0.6664
Portata 52W:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Confronta RLMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.641 | 862.34M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.57 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.61 | 121.44M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1521 | 322.13M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.82 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-06-05 | Downgrade | Goldman | Neutral → Sell |
| 2022-10-14 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-10-14 | Downgrade | Truist | Buy → Hold |
| 2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Iniziato | Mizuho | Buy |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-10-28 | Downgrade | Goldman | Buy → Neutral |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-04 | Iniziato | SunTrust | Buy |
| 2020-04-21 | Iniziato | Goldman | Buy |
| 2020-01-27 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Advanced analytics toolkit walkthrough for Relmada Therapeutics Inc.Daily Pattern Analysis with Return Forecast - Newser
Is a relief rally coming for Relmada Therapeutics Inc. holdersIntraday Price Forecast Using Volume Models - Newser
What’s next for Relmada Therapeutics Inc. stock priceFree Early Entry Tips With Low Risk Zone - Newser
Published on: 2025-08-04 12:29:06 - metal.it
Will a bounce in Relmada Therapeutics Inc. offer an exitWeekly Setup Summary for Risk Controlled Trades - Newser
What are the latest earnings results for Relmada Therapeutics Inc.Get alerts on top growth stocks daily - Jammu Links News
Why Relmada Therapeutics Inc. stock attracts strong analyst attentionFree Alert Feed for Momentum Based Picks - Newser
What makes Relmada Therapeutics Inc. stock price move sharplyMarket Downturn Defense Strategy Analysis - Newser
Using portfolio simulators with Relmada Therapeutics Inc. includedShort-Term Stock Trend Forecast Guide - Newser
What catalysts could drive Relmada Therapeutics Inc. stock higher in 2025Unlock powerful trading signals for profits - Jammu Links News
How volatile is Relmada Therapeutics Inc. stock compared to the marketRobust investment performance - Jammu Links News
How does Relmada Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for steady growth - Jammu Links News
What institutional investors are buying Relmada Therapeutics Inc. stockInvest in stocks with strong fundamentals - Jammu Links News
What analysts say about Relmada Therapeutics Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
What drives Relmada Therapeutics Inc. stock priceCapitalize on emerging market opportunities - Jammu Links News
Real time breakdown of Relmada Therapeutics Inc. stock performanceOversold Reversal Picks with Buy Zone - Newser
Using fundamentals and technicals on Relmada Therapeutics Inc.Capital Secure Pattern Signal Analysis Sheet - Newser
What is the risk reward ratio of investing in Relmada Therapeutics Inc. stockAccess daily stock market expert updates - Jammu Links News
What are analysts’ price targets for Relmada Therapeutics Inc. in the next 12 monthsUnbelievable profit margins - Jammu Links News
How strong is Relmada Therapeutics Inc. company’s balance sheetInvest in stocks with strong fundamentals - Jammu Links News
Why is Relmada Therapeutics Inc. stock attracting strong analyst attentionStay informed with daily expert analysis - Jammu Links News
What are Relmada Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News
Relmada Therapeutics (RLMD.US) will release its earnings reports after the market closes on August 7th. - 富途牛牛
How to monitor Relmada Therapeutics Inc. with trend dashboardsSmart Trade Mapping with Entry Details - Newser
Building trade automation scripts for Relmada Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Manila Times
Relmada Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Oncology and CNS Pipeline - Stock Titan
Relmada Therapeutics Inc. At Decision Level — Rebound or ResistanceReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 2.3% – Here’s What Happened - Defense World
Does Relmada Therapeutics Inc. stock perform well during market downturnsBeginner Investor Growth Plan For Every Investor - Jammu Links News
When is Relmada Therapeutics Inc. stock expected to show significant growthPost Market Outlook For Every Investor - Jammu Links News
Why Relmada Therapeutics Inc. stock attracts strong analyst attention Monthly Trade Result and Signal Summary - Newser
Why Relmada Therapeutics Inc. stock attracts strong analyst attention AI Screener Based Stock Summary Report - metal.it
Is it the right time to buy Relmada Therapeutics Inc. stockPhenomenal returns - Jammu Links News
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relmada Therapeutics Inc Azioni (RLMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 11 '24 |
Buy |
2.99 |
51,407 |
153,707 |
384,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
0.40%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):